oxybutynin has been researched along with Sialorrhea in 4 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Sialorrhea: Increased salivary flow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To describe a case of clozapine-induced sialorrhea alleviated by immediate-release oxybutynin." | 7.77 | Immediate-release oxybutynin for the treatment of clozapine-induced sialorrhea. ( Jacobson, MJ; Leung, JG; Puri, NV, 2011) |
| "To describe a case of clozapine-induced sialorrhea alleviated by immediate-release oxybutynin." | 3.77 | Immediate-release oxybutynin for the treatment of clozapine-induced sialorrhea. ( Jacobson, MJ; Leung, JG; Puri, NV, 2011) |
| "Primary outcome: Drooling Impact Scale (DIS) score at week-4." | 2.87 | Drooling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. ( Cadwgan, J; Cole, M; Colver, AF; O'Hare, AE; Parr, JR; Pennington, L; Stocken, D; Todhunter, E; Tuffrey, C; Williams, J, 2018) |
| "Drooling is common in children with neurological disorders, but its management is very challenging, Scopolamine transdermal patch (STP) appears to be useful in controlling drooling, although it is not approved for this indication and there are limited clinical studies about its effectiveness." | 1.56 | Efficacy of scopolamine transdermal patch in children with sialorrhea in a pediatric tertiary care hospital. ( Abolfotouh, MA; Al Jeraisy, M; AlFuraih, M; AlKhalifah, B; AlOtaibi, H; AlSaif, R, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leung, JG | 1 |
| Puri, NV | 1 |
| Jacobson, MJ | 1 |
| Al Jeraisy, M | 1 |
| AlFuraih, M | 1 |
| AlSaif, R | 1 |
| AlKhalifah, B | 1 |
| AlOtaibi, H | 1 |
| Abolfotouh, MA | 1 |
| Parr, JR | 1 |
| Todhunter, E | 1 |
| Pennington, L | 1 |
| Stocken, D | 1 |
| Cadwgan, J | 1 |
| O'Hare, AE | 1 |
| Tuffrey, C | 1 |
| Williams, J | 1 |
| Cole, M | 1 |
| Colver, AF | 1 |
| Chowdhury, NA | 1 |
| Sewatsky, ML | 1 |
| Kim, H | 1 |
1 trial available for oxybutynin and Sialorrhea
| Article | Year |
|---|---|
Drooling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Cholinergic Antagonists; Drug Administrat | 2018 |
3 other studies available for oxybutynin and Sialorrhea
| Article | Year |
|---|---|
Immediate-release oxybutynin for the treatment of clozapine-induced sialorrhea.
Topics: Antipsychotic Agents; Bipolar Disorder; Clozapine; Female; Humans; Mandelic Acids; Middle Aged; Musc | 2011 |
Efficacy of scopolamine transdermal patch in children with sialorrhea in a pediatric tertiary care hospital.
Topics: Adolescent; Cerebral Palsy; Child; Child, Preschool; Humans; Retrospective Studies; Saudi Arabia; Sc | 2020 |
Transdermal Scopolamine Withdrawal Syndrome Case Report in the Pediatric Cerebral Palsy Population.
Topics: Adolescent; Antiemetics; Botulinum Toxins, Type A; Cerebral Palsy; Delayed Diagnosis; Humans; Inject | 2017 |